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Background  and  purpose      Thrombophilia  represents  a  risk 
factor both for idiopathic and secondary osteonecrosis (ON). We 
evaluated whether clotting changes in idiopathic ON were differ-
ent from corticosteroid-associated ON. As platelet-rich plasma 
has been proposed as an adjuvant in surgery, we also assessed 
whether platelet and serum growth factors were similar to those 
in healthy subjects. 
Methods   18 patients with idiopathic ON and 18 with corticoste-
roid-associated ON were compared with 44 controls for acquired 
and inherited thrombophilia. Platelet factor 4 (PF4), transform-
ing growth factor-β1, platelet-derived growth factor-BB (PDGF-
BB), and vascular endothelial growth factor were assayed in the 
supernatants of thrombin-activated platelets, in platelet lysates, 
and in serum from 14 ON patients and 10 controls. 
Results   Idiopathic ON patients had higher plasminogen levels 
(median 118%) than controls (101%) (p = 0.02). Those with cor-
ticosteroid-associated ON had significantly higher D-dimer (333 
ng/mL) and lower protein C levels (129%) than controls (164 
ng/mL, p = 0.004; 160%, p = 0.02). The frequency of inherited 
thrombophilia was not different from the controls. No statistically 
significant differences were found between idiopathic and corti-
costeroid-associated ON. 20 of the 36 ON patients were smokers. 
(The controls were selected from smokers because nicotine favors 
hypercoagulability). ON patients had significantly higher serum 
PF4 levels (7,383 IU/mL) and PDGF-BB levels (3.1 ng/mL) than 
controls (4,697 IU/mL, p = 0.005; 2.2 ng/mL, p = 0.02).
Interpretation   Acquired hypercoagulability was common in 
both ON types, but the specific changes varied. The release of GF 
from platelets was not affected, providing a biological basis for 
platelet-rich plasma being used as an adjuvant in surgical treat-
ment.
 
Osteonecrosis (ON) of the femoral head may lead to joint col-
lapse and arthritis. In the late stages of the disease, when pain, 
stiffness, and disability cannot be controlled by non-surgical 
means, the treatment is total hip replacement. At the early 
stages, when less invasive treatments to preserve the femoral 
head such as core decompression, osteotomy, or vascularized 
bone grafting—or even non-invasive therapy, such as pharma-
cological measures, electrical stimulation, shock waves, and 
electromagnetic fields (Mont et al. 2007)—can prevent the 
affected bone from collapsing, the disease can be diagnosed 
only with magnetic resonance imaging. A history of one or 
more risk factors strengthen the suspicion of ON.
It is commonly postulated that ON is caused by reduced 
blood flow to the bone (Assouline-Dayan et al. 2002). Vascu-
lar occlusion and ischemia may depend on different underly-
ing conditions such as trauma, radiation, chemotherapy, cais-
son disease, alcoholism, or high-dose corticosteroid therapy. 
However,  predisposing  conditions  are  not  always  evident; 
about 20% of cases appear to be idiopathic in origin without 
any associated cause (Min et al. 2008). It has been hypoth-
esized that inherited or acquired thrombophilia and hypofi-
brinolysis may be risk factors for idiophatic ON (Glueck et 
al. 2003). However, patients with ON seldom relate having 
a familial or personal history of thromboembolism and the 
results of the specific alterations in the clotting system or of 
fibrinolysis are contrasting (Mehsen et al. 2009). Moreover, 
research has been focused on idiopathic ON without consider-
ing that thrombophilia also represents an additional risk factor 
for secondary ON. 
On the basis of the high concentration of growth factors 
(GFs)  released  by  a-granules,  platelet-rich  plasma  (PRP) 
has been proposed as an adjuvant to improve angiogenesis 
and osteogenesis in the surgical treatment of ON (Yokota et Acta Orthopaedica 2011; 82 (1): 42–49  43
al. 2008, Marx 2009). However, nothing is known about the 
levels of platelet GFs in ON.
We evaluated whether patients affected by idiopathic ON 
had different plasmatic and genetic abnormalities of throm-
bophilia  and  fibrinolysis  from  patients  with  corticosteroid-
associated ON. We also assessed whether the platelet levels 
of osteogenic and angiogenic GFs were similar to those of 
healthy subjects. 
Patients and methods 
The study protocol was approved by the institutional ethical 
committee on human research and was performed according 
to the Helsinki Declaration of 1975, as revised in 2000. The 
study  included  patients  with  idiopathic  and  corticosteroid-
associated ON of the femoral head who had been diagnosed 
by clinical and radiological criteria and were hospitalized for 
hip surgery. Before surgery, an informed consent document 
was signed, the familial and clinical history was registered, 
and a sample of blood was taken. The patients had not taken 
heparin, oral anticoagulants, aspirin, or other platelet antiag-
gregants in the 2 weeks preceding blood collection. Patients 
with platelet disorders or platelet number less than 1 × 105/µL 
were excluded. 
18 patients had idiopathic ON and in 18 individuals the 
disease  developed  after  corticosteroid  treatment.  Contrary 
to other studies, we did not find any case of alcohol-related 
ON. The consumption of alcohol was occasional or limited 
to half or one glass of wine per meal. There were no statis-
tically significant differences in age and sex between idio-
pathic and corticosteroid-associated ON. The patients were 
compared with 44 healthy individuals who were similar to the 
patients regarding age and sex, and who had no clinical dis-
order or history of thrombosis (Table 1). A familial history of 
thrombosis was seldom present: there were 3 such cases with 
idiopathic ON and 1 such case with corticosteroid-associated 
ON. None of the individuals had any history of deep venous 
thrombosis, embolism, or myocardial infarction. Risk factors 
for thrombosis were seldom present: arterial hypertension (3 
patients with idiopathic ON and 3 patients with corticosteroid-
associated ON) and obesity (Lijnen 2009) (1 case with idio-
pathic ON and 2 patients with corticosteroid-associated ON). 
As smoking was common in patients with either idiopathic 
or  corticosteroid-associated  ON,  the  healthy  controls  were 
selected from a population of smokers to avoid bias based on 
hypercoagulability (that is favored by nicotine (Benowitz et 
al. 1993)) and to make a better comparison with ON patients. 
Staging was performed according to the radiographic criteria 
of the working group of the Japanese Specific Disease Inves-
tigation Committee under the auspices of the Japanese Min-
istry of Health, Labour and Welfare, to establish criteria for 
diagnosis and management of idiopathic ON of the femoral 
head (Sugano et al. 2002) (Table 2). There were no statisti-
cally significant differences in stage between the ON types, as 
analyzed with the Chi-square test.
In a group of 14 ON patients (mean age 35 (19–64) years, 
13 males) selected on the basis of surgery, platelet factor 4 
(PF4) and GF levels in platelets and serum were compared 
with those in 10 healthy controls. 12 patients were affected by 
idiopathic ON and 2 patients by secondary ON (1 by posttrau-
matic ON and 1 by corticosteroid-associated ON). Age and 
sex were similar in the controls and patients.
Blood collection and handling
For the clotting tests and for PF4 and GF assays, the blood was 
collected in 0.129 M sodium citrate. Within 2 h of collection, 
the samples for the clotting tests were centrifuged at 600 g 
for 10 min. The plasma was frozen in aliquots at –70°C. The 
samples for the assays of PF4 and GF were centrifuged at 180 
g for 5 min in order to separate PRP from erythrocytes and 
leukocytes. Then the PRP was transferred to a clean tube and 
centrifuged at 600 g for 15 min. The platelets were pelleted 
at the bottom of the tube; platelet-poor plasma (PPP) in the 
upper phase was carefully transferred to a clean tube. Platelet 
number was adjusted to 1 × 106/µL with PPP. Then the PRP 
was divided into 2 aliquots. In the first aliquot, platelets were 
Table 1. Profiles of 18 patients with idiopathic ON, 18 patients with 
corticosteroid-associated ON, and 44 healthy controls. For qualita-
tive variables, the number of patients is reported
Variable  Idiopathic  Corticosteroid-  Healthy
  ON  associated ON  controls
Sex
  male  15  12  33
  female    3     6  11 
Age (years)
  mean (SD)  45 (12)  41 (10)  45 (10)
  median (range)  41 (27–74)  42 (25–64)  44 (22–64)
Bilaterality    9    9  –
Smoking habit
  no. of smokers  13    7  42
  no. of non-smokers    3    6    1
  no. of unknown    2     5    1
Table 2. Stages of osteonecrosis (ON) in 18 patients with idiopathic 
ON and 18 patients with corticosteroid-associated ON, according 
to the radiographic criteria of the Japanese Specific Disease Inves-
tigation Committee under the auspices of the Japanese Ministry 
of Health, Labour and Welfare (Sugano et al. 2002). The number of 
patients for each stage is reported. In 1 patient with idiopathic ON, 
the radiographs did not show any lesions and the clinical diagnosis 
was confirmed by magnetic resonance imaging 
  Stage 
  1  2  3A  3B  4
Idiopathic ON   0  2   7   5   3 
Corticosteroid-associated ON  0  2  6  5  544  Acta Orthopaedica 2011; 82 (1): 42–49
lysed by 2 cycles of freeze-thawing at –80°C. In the second 
aliquot, the platelet release reaction was induced by adding 
5 U/mL bovine thrombin (Sigma-Aldrich Corp., St. Louis, 
MI) for 30 min at room temperature, the samples were centri-
fuged, and the supernatants (from platelet release) were stored 
at –80°C prior to assay. PF4 and GF were also determined in 
serum, which was stored at –80°C after centrifugation at 600 g 
for 45 min. Blood for genetic analysis was drawn in tubes con-
taining ethylenediaminetetraacetic acid and stored at –20°C. 
Antithrombin III
Antithrombin III was determined with a chromogenic assay 
(HemosIL  Antithrombin,  Instrumentation  Laboratory,  Lex-
ington, MA). The percentage of antithrombin III activity in 
the samples was extrapolated from a standard curve of scalar 
dilutions of Calibration Plasma (Instrumentation Laboratory) 
according to the linear regression function. 
Protein C
Protein C activity was determined with a clotting test (Hemo-
sIL ProClot APTT-SP, Instrumentation Laboratory) based on 
the prolongation of APTT in the presence of activated protein 
C, generated by an activator derived from snake venom. The 
percentage of protein C activity was extrapolated by a stan-
dard curve of scalar dilutions of Calibration Plasma according 
to the linear regression function. 
D-dimer
D-dimer  was  measured  by  enzyme  immunoassay  (Assera-
chrom D-DI; Diagnostica Stago, Asnieres, France). The stan-
dard curve was plotted using the point-to-point method. 
Plasminogen
Plasminogen  was  determined  with  a  chromogenic  assay 
(HemosIL  Plasminogen,  Instrumentation  Laboratory).  The 
percentage  of  activity  of  plasminogen  in  the  samples  was 
extrapolated from a standard curve of scalar dilutions of Cali-
bration Plasma according to the linear regression function.
Plasminogen activator inhibitor-1
PAI-1 was detected in citrated plasma by enzyme immuno-
assay (AssayMax Human Plasminogen Activator Inhibitor-1 
(PAI-1) ELISA Kit; Assaypro, St. Charles, MO). The standard 
curve was plotted by regression analysis using log-log curve 
fit. 
Platelet factor 4 and growth factor assays
PF4,  transforming  growth  factor-β1  (TGF-β1),  platelet-
derived growth factor-BB (PDGF-BB), and vascular endothe-
lial growth factor-A (VEGF-A) were determined in platelet 
releasates, lysates, and in serum with enzyme immunoassays 
according to the directions of the manufacturers (Asserachrom 
PF4: Stago, Asnieres, France; TGF-β1 Emax ImmunoAssay 
System:  Promega  Corp.,  Madison, WI;  Quantikine  Human 
PDGF-BB:  R&D  Systems  Inc.,  Minneapolis,  MN;  DuoSet 
Human VEGF: R&D Systems). Before assay of TGF-β1, the 
samples were activated with 1N HCl to pH 3.0 or lower for 15 
min and then neutralized with 1N NaOH to pH 7.6.
DNA purification
Total DNA was purified from whole blood (QIAamp DNA 
Mini  Kit;  Qiagen  GmbH,  Hilden,  Germany)  and  stored  at 
–20°C.
Factor V Leiden mutation
The single point mutation (G to A at position 1691) of the 
factor V gene (factor V Leiden) was detected using real-time 
PCR (Factor V Leiden Kit; Roche Applied Science, Monza, 
Italy) on the LightCycler 1.2 instrument (Roche Applied Sci-
ence). The amplification program consisted of a first denatur-
ation at 95°C for 30 seconds and 45 cycles of amplification 
(annealing at 55°C for 10 seconds and extension at 72°C for 
5 seconds).
Prothrombin gene mutation
The prothrombin gene mutation 20210A was detected using 
real-time PCR (Factor II (Prothrombin) G20210A Kit; Roche 
Applied  Science)  on  the  LightCycler  1.2  instrument.  The 
amplification program consisted of a first denaturation at 95°C 
for 30 seconds and 45 cycles of amplification (annealing at 
55°C for 10 seconds and extension at 72°C for 5 seconds).
PAI-1 gene 4G/5G polymorphism
The  PAI-1  gene  4G/5G  polymorphism  was  detected  using 
real-time PCR (huPlasminogen activator inhibitor 4/5G: Tib-
Molbiol, Genoa, Italy; LC DNA Master Hybridization Probes: 
Roche Applied Science) on the LightCycler 1.2 instrument. 
Five µL of the DNA template was added to a master mix com-
posed of 2.2 µL 4 mM MgCl2, 2 µL LC DNA Master Hybrid-
ization Probes and 1 µL of each of the primers huPAI 4/5G, in 
a total volume of 20 µL. The amplification program consisted 
of a denaturation step at 95°C for 60 seconds followed by 37 
cycles of amplification (denaturation at 95°C for 1 seconds, 
annealing at 64°C for 10 seconds, and extension at 72°C for 
13 seconds).
Statistics
Statistical  evaluations  were  performed  using  StatView  for 
Windows version 5.0.1 (SAS Institute, Cary, NC). The sta-
tistical power was calculated with Simple Interactive Statisti-
cal Analysis (SISA) (http://www.quantitativeskills.com/sisa/). 
Quantitative results are reported as arithmetic mean, standard 
deviation  (SD),  median,  and  minimum-maximum  range. 
Because  normal  distribution  and  homogeneity  of  variance 
were not verified by Levene’s test, the differences among the 
groups were evaluated with Kruskal-Wallis test, and the dif-
ferences between ON groups, or each ON group and the nega-
tive control, were evaluated with the Mann-Whitney U-test. Acta Orthopaedica 2011; 82 (1): 42–49  45
The differences between the concentrations of GFs in serum 
and in platelet releasates or lysates were evaluated with the 
Wilcoxon signed rank test. The differences were considered 
significant at p-values < 0.05. 
Results
Coagulation inhibitors
In corticosteroid-associated ON, protein C activity was sta-
tistically significantly lower; however, in the idiopathic type 
the results were similar to the healthy controls. There were 
no statistically significant differences between idiopathic and 
corticosteroid-associated ON. Only non-relevant differences 
were demonstrated for antithrombin III levels, either between 
the 2 groups of patients or between each group and the nega-
tive control (Table 3). 
Hypercoagulability
The patients with corticosteroid-associated ON showed sta-
tistically  significantly  higher  D-dimer  concentrations  than 
the healthy controls. In idiopathic ON, a trend towards high 
levels of D-dimer was observed but this was not statistically 
significant. No statistically significant differences were found 
between idiopathic and corticosteroid-associated ON (Table 4). 
Fibrinolysis
The patients with idiopathic ON had statistically significantly 
higher plasminogen activity than the controls. The patients 
with corticosteroid-associated ON had plasminogen concen-
trations similar to the healthy controls. No statistically signifi-
cant differences were found between the 2 types of ON. No 
significant differences in plasma concentration of PAI-1 were 
seen, either between the patients and the controls or when 
comparing the different types of ON (Table 4). 
Hypercoagulability and fibrinolysis in smokers
In smokers, D-dimer levels were significantly different in idio-
pathic ON, in corticosteroid-associated ON, and in healthy 
controls  (Kruskall-Wallis  test:  p  =  0.02),  and  they  were 
increased in ON (Mann-Whitney U test: p = 0.006). In partic-
ular, smokers with idiopathic ON showed statistically signifi-
cantly higher D-dimer levels than controls. In these patients, 
a trend was also evident regarding higher plasma PAI-1 levels 
than controls (Table 5). No statistically significant differences 
Table 3. Protein C and antithrombin III activity in 18 patients with 
idiopathic ON, 18 patients with corticosteroid-associated ON, and 
44 healthy controls 
  Protein C  Antithrombin III
  (%)  (%) 
Idiopathic ON 
  mean (SD)  174 (50)  110 (22)
  median  163  115
  minimum–maximum range     95–273    72–145
Corticosteroid-associated ON
  mean (SD)  138 (42) a  103 (17)
  median  129  107
  minimum–maximum range    85–243    68–125
Healthy controls 
  mean (SD)  167 (35)  102 (18)
  median  160    98
  minimum-–maximum range    99–237    80–146
a p = 0.02 when compared with healthy controls.
Table 4. Plasma levels of D-dimer, plasminogen, and PAI-1 in 18 
patients with idiopathic ON, 18 patients with corticosteroid-associ-
ated ON, and 44 healthy controls
  D-dimer  Plasminogen   PAI-1
  (ng/mL)  (%)  (ng/mL)
Idiopathic ON 
  mean (SD)  241 (132)  115 (18) b  4.6 (2.6)
  median  173  118  4.7
  range  86–553  72–149  1.2–10.5
Corticosteroid-associated ON
  mean (SD)  384 (274) a  104 (15)  3.6 (1.9)
  median  333  101  2.9
  range  85–1000  84–129   1.5–7.1
Healthy controls 
  mean (SD)  173 (72)  104 (16)  3.4 (1.8)
  median  164  101  3.2
  range  65–338  65–129  0.6–8
 a p = 0.004 vs. healthy controls
 b p = 0.02 vs. healthy controls
Table 5. Coagulation and fibrinolysis in smokers (13 with idiopathic 
ON, 7 with corticosteroid-associated ON, and 42 healthy controls) 
  Idiopathic   Corticosteroid-   Healthy 
  ON  associated ON  controls
Protein C (%)
  mean (SD)  178 (57)  152 (52)  165 (39)
  median  163  148  158
  range     95–273    97–243    99–237
Antithrombin III (%)
  mean (SD)  107 (22)  104 (19)  103 (19)
  median  107  112.7    99
  range    72–134    68–117    80–146
D-dimer (ng/mL)
  mean (SD)  227 (118) a  239 (131)  172 (73)
  median  173  235  158
  range  145–553    85–419    65–338
Plasminogen (%)
  mean (SD)  116 (20)  108 (18)  104 (16)
  median  118  105  102
  range     72–149    84–129    65–129
PAI-1 (ng/mL)
  mean (SD)  5.3 (2.5) b  3.8 (2.3)  3.4 (1.8)
  median  4.8  2.6  3.2
  range  1.8–10.5  2–7  0.6–8
a p = 0.01 when compared with healthy controls; 
b p = 0.05 when compared with healthy controls.46  Acta Orthopaedica 2011; 82 (1): 42–49
in all parameters examined were found between smokers with 
corticosteroid-associated ON and those with idiopathic ON or 
controls. 
Platelet factor 4 and growth factor assays
A high degree of variability was seen in platelet and serum 
levels of PF4 and GFs, both in patients and in healthy controls. 
The levels of GFs in releasates were higher than in serum; in 
particular, PDGF-BB was 2.7- (2.1-) fold higher, TGF-β1 was 
1.7- (2.3-) fold higher and VEGF was 1.5- (0.3-) fold higher. 
The lysate:serum ratio was higher than the releasate:serum 
ratio: for PDGF-BB it was 3.4- (1.8-) fold higher, for TGF-β1 
it was 4.8- (4.5-) fold higher and for VEGF it was 1.3- (0.5-) 
fold  higher.  Even  though  the  GF  levels  in  releasates  and 
lysates from ON patients were higher than those from healthy 
controls, no statistically significant differences were found. 
Instead, the serum concentrations of PF4 and PDGF-BB in 
ON patients were statistically significantly higher than in the 
controls (Table 6). 
Heritable thrombophilia and hypofibrinolysis
Homozygosity  or  heterozygosity  for  factor  V  Leiden  was 
present in only 2 patients affected by corticosteroid-associ-
ated ON. Factor V Leiden was not detected in any patients 
with idiopathic ON or in any controls. Homozygosity for the 
prothrombin gene mutation was not found in any patients or 
controls; heterozygosity was present in only 2 patients with 
idiopathic ON and in 1 control. The genotypes 4G/5G and 
4G/4G of the PAI-1 gene were demonstrated in 7 and 6 of 18 
patients with idiopathic ON, and in 9 and 4 of 18 patients with 
corticosteroid-associated ON. The frequency of 4G/4G homo-
zygosity was also high in healthy controls (19/44), while 16 of 
the 44 control subjects were heterozygous. 
Discussion 
We hypothesized that the alterations in the clotting system or 
in fibrinolysis in idiopathic ON may be different from those in 
corticosteroid-associated ON. The secondary hypothesis was 
that the levels of GFs in ON platelets are similar to or higher 
than in those of healthy subjects, thus supporting the use of 
PRP as an adjuvant for the treatment of ON. 
Although the idiopathic and corticosteroid-associated ON 
groups were homogenous regarding age, sex, and stage, one 
limitation of the study may be the low number of cases. The 2 
types of ON showed different alterations in the clotting tests. 
In particular, higher levels of plasminogen were detected in 
idiopathic ON while lower protein C activity and higher con-
centrations of D-dimer were found in corticosteroid-associ-
ated ON. 
The high plasminogen levels in idiopathic ON may have 
several explanations. Some degree of synovial inflammation 
has been shown in ON and it was hypothesized to play a role 
in the disease progression (Rabquer et al. 2009). Plasminogen, 
which increases in phlogosis, could be a systemic marker of 
the inflammatory state present in ON, such as erythrosedimen-
tation rate, which has been found to be elevated in 78% of ON 
patients (Séguin et al. 2008). Also, the trend toward higher 
levels of PAI-1—which was particularly evident in smokers 
with idiopathic ON—may have contributed to the increase 
in  plasminogen.  In  fact,  PAI-1  inhibits  tissue  plasminogen 
activator and therefore generation of plasmin from plasmino-
gen. This trend of increased PAI-1 levels was only partially 
explained by homozygosity for the 4G/4G polymorphism of 
the PAI-1 gene, which leads to higher transcription of the gene 
and therefore higher production of PAI-1 protein (Asano et al. 
2004). Notably, in our patients the frequency of homozygosity 
for the 4G/4G polymorphism was lower than in the healthy 
controls, and was also lower than the 41% reported by Glueck 
Table 6. Platelet factor 4 (PF4) and growth factors in releasates, platelet lysates, platelet-poor plasma (PPP), and serum in 14 patients with 
osteonecrosis (ON) and in 10 controls (Ctr). Releasates and lysates were obtained from platelet concentrates, after adjustment of platelet 
number to 1 × 106 / mL
 
Sample  PF4 (IU/mL)   TGF-β1 (ng/mL)  PDGF-BB (ng/mL)  VEGF-A (pg/mL) 
  ON  Control  ON  Control  ON  Control  ON  Control
Releasates
  mean (SD)    7,661 (2,648)    6,856 (2,171)  55 (76)  28 (35)    8.1 (3.5)  6.4 (2.6)  165 (83)    105 (88)
  median    8,265    6,939  21  16    8.1  6.5  183  105
  range    4,568–10,000    3,269–10,000    2–200    2–105    2.9–13.7  2.5–11.1      9–235      9–230
Lysates
  mean (SD)    8,621 (3,231)     9,042 (1,670)  146 (85)  99 (68)  11.9 (7.4)   10.8 (6.3)  206 (180)  172 (134)
  median  10,000  10,000  200  69  11.1  9.2  152  138
  range    2,031–10,000    4,717–10,000    33–200  26–196    2.7–26.8  4–26      9–570      9–402
Serum
  mean (SD)    7,405 (985) a     5,142 (1240)    38 (18)  26 (15)    4.2 (3.6) b  2.3 (0.5)  215 (210)  182 (134)
  median    7,383    4,697    50  29    3.1  2.2  155  160
  range    5,777–8,553    3,576–7,165    14.6–50    2.5–50    1.1–13.5  1.3–3.1      9–628      9–493
 a p = 0.005 when compared with controls;  b p = 0.02 when compared with controls.Acta Orthopaedica 2011; 82 (1): 42–49  47
et al. (1999) for ON. Inflammation (Aso 2007, Kruithof 2008) 
or endothelial activation (Salgado et al. 1994) may be another 
possible explanation for the increase in PAI-1. Endothelial 
activation, which has been reported in ON (Séguin et al. 2008), 
could have caused the increase in PAI-1 in our patients. One 
possible limitation of our data was the low sample number. 
The statistical power analysis based on idiopathic ON-control 
differences in plasminogen revealed a power of 62% for a = 
0.05. Thus, these results should be considered preliminary and 
they require confirmation.
Normal or low levels of plasminogen have been reported 
by other authors in both ON and Perthes’ disease, which has 
a similar pathogenesis. Lee et al. (2003) did not show any 
variation between non-traumatic ON patients and controls. In 
Perthes’ disease, reduced plasminogen was reported by Pósán 
et al. (2003), but normal levels were reported by Koo et al. 
(2002). These discordant results may depend on ethnic differ-
ences, as hypothesized by Lee et al. (2003). On the other hand, 
contrasting data have been reported in the literature for other 
clotting or fibrinolytic alterations in ON, and in Perthes’ dis-
ease. Probably different thrombophilic changes, but all drivers 
to hypercoagulability, may be involved in ON pathogenesis 
among different ethnic groups or even among different indi-
viduals. 
For all the parameters examined, no statistically significant 
differences between idiopathic and corticosteroid-associated 
ON were found. Corticosteroid-associated ON showed pecu-
liar alterations, consisting of a decrease in protein C and in an 
increase in D-dimer relative to healthy controls. A possible 
limitation of the finding of a reduction in protein C in corti-
costeroid-associated ON was the fact that the statistical power 
was 72% for a = 0.05; thus, our findings require to be con-
firmed by further studies. Other authors have found reduced 
protein C activity in non-traumatic ON (Zalavras et al. 2000). 
In Perthes’ disease, discordant results have been reported for 
protein C: some authors have not found any changes (Almeida 
Matos 2008) while others have found reduced levels (Mehta 
et al. 2006). 
Instead, the statistical power analysis based on difference 
between  corticosteroid-associated  ON  and  controls  regard-
ing D-dimer levels revealed a power of 95% for a = 0.01. An 
increase in D-dimer was reported in 25% and 21% of patients 
with idiopathic or secondary ON, respectively, as a conse-
quence of the hypercoagulability that also induced ON (Pósán 
et al. 2003). Corticosteroid treatment did not affect D-dimer 
levels in healthy volunteers (Brotman et al. 2006), but induced 
thrombosis and ON in rabbits, when associated with a low 
dose of lipopolysaccharide (Wu et al. 2008). Even though glu-
cocorticoids may increase PAI-1 gene transcription (Halleux 
et al. 1999) and plasma levels (Kerachian et al. 2009) in cor-
ticosteroid-associated ON, PAI-1 concentration was similar 
to that in the healthy controls, probably because the patients 
were not taking corticosteroids when they were enrolled. 
We found a low frequency of inherited thrombophilia both 
in idiopathic ON and corticosteroid-associated ON. The fre-
quencies of factor V Leiden and prothrombin gene mutations 
were similar to those in the controls, contrary to what has been 
asserted by some authors who have hypothesized that idio-
pathic ON might be favored by factor V Leiden or prothrom-
bin gene mutation (Björkman et al. 2004). 
Interestingly,  55%  of  the  ON  patients  were  smokers,  as 
compared to a rate of 23% in the general population (Activi-
ties for the prevention of smoking—2009 report, Ministry of 
Health,  Italy,  http://www.salute.gov.it/imgs/C_17_pubblica-
zioni_1161_ulteriorallegiati_ulterioreallegato_0_alleg.pdf). 
Other researchers have found a strong association between 
tobacco consumption and risk of ON. Mehsen et al. (2009) 
found a frequency of 69% smokers in ON patients and a fre-
quency of 38% smokers in controls. Sakaguchi et al. (2010) 
observed that more patients who developed ON after corti-
costeroid therapy had a smoking habit (68%) than controls 
(50%). Also, in Perthes’ disease an association between the 
femoral lesion and smoking by the mother during pregnancy 
or passive smoking after birth has been demonstrated (Glueck 
et al. 1998). Nicotine has been reported to cause vasocon-
striction (Winniford et al. 1987) and to induce bovine and 
human endothelial cells to produce PAI-1 (Kuo et al. 1989, 
Zidovetzki et al. 1999). Increased plasma levels of D-dimer 
(Wannamethee et al. 2005) and PAI-1 (Tapson 2005) have 
been found in healthy smokers. 
In our study, D-dimer levels were higher in smokers with 
ON than in smokers in the control group. This result was more 
evident in smokers with idiopathic ON. In these patients, a 
trend of higher plasma levels of PAI-1 was also found. Thus, 
we could hypothesize that smoking is only one of several risk 
factors for idiopathic ON. Other causes may induce hyper-
coagulability,  which  is  important  for  ON  pathogenesis.  In 
smokers with corticosteroid-associated ON, D-dimer levels 
were not statistically significantly different from those in the 
controls, which is contrary to what was observed when we 
considered smokers and non-smokers together. In this group, 
other  causes,  independent  of  smoking  and  present  also  in 
non-smokers,  could  have  induced  the  increase  in  D-dimer. 
Mehsen et al. (2009) did not consider the laboratory tests of 
ON patients and controls separately according to their smok-
ing habits. Sakaguchi et al. (2010) did not perform any labora-
tory test because they considered only anamnestic risk factors 
for corticosteroid-associated ON. On the basis of the above 
considerations, smoking may be considered to be more of a 
possible risk factor when associated with other causes than an 
etiological factor of ON, through its proinflammatory, proco-
agulant, antifibrinolytic, and antiendothelial effects (Yanbaeva 
et al. 2007). 
In order to establish a scientific basis for the use of platelet-
rich plasma in ON, we determined the levels of some osteo-
genic and angiogenic GFs in platelet lysates and releasates. 
The levels of platelet GFs are known in healthy blood donors 
(Zimmermann et al. 2003), but the effects of bone diseases 48  Acta Orthopaedica 2011; 82 (1): 42–49
such as ON on the concentrations are unknown. As GF levels 
in plasma originate from different cell types, we determined 
also PF4, which is specific for platelet a-granules (Kaplan 
1978). In releasates, PDGF-BB, TGF-β1, and VEGF origi-
nated from platelet activation induced by thrombin and their 
levels were lower than in lysates, which contained the total 
amount present in platelets. Some of the GFs were entrapped 
in the fibrin network and were slowly released during clot 
retraction. The levels of GFs in ON were similar to or higher 
than in healthy controls. These results support the use of PRP 
as an adjuvant in ON treatment. The higher concentrations of 
PF4 and PDGF-BB in the serum of ON patients may be due to 
the increased platelet activation associated with the thrombo-
philic state (Pósán et al. 2003).
In  conclusion,  we  did  not  detect  statistically  significant 
differences in clotting tests between idiopathic and cortico-
steroid-associated ON. In comparison with healthy controls, 
idiopathic ON showed higher plasminogen activity; cortico-
steroid-associated ON had lower protein C levels and higher 
D-dimer levels. However, these results require to be confirmed 
by further studies on a larger number of patients, particularly 
the data regarding plasminogen and protein C. In both groups 
of patients, the frequency of heritable thrombophilia and fibri-
nolysis was similar to that for the controls. Thus, the results 
of this preliminary study support the idea that both idiopathic 
and  corticosteroid-associated  ON  are  favored  by  acquired 
hypercoagulability, but at a subclinical level. The high levels 
of PF4 in releasates showed that platelet release reaction is 
not affected in ON. The concentrations of GFs in releasates 
and lysates from ON patients were similar to those in healthy 
subjects. This result provides a biological basis for the use of 
PRP in ON treatment. 
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